Are young injection drug users ready and willing to participate in preventive HCV vaccine trials?
Trials to evaluate the efficacy of preventive HCV vaccines will need participation from high risk HCV seronegative injection drug users (IDUs). To guide trial planning, we assessed willingness of young IDU in San Francisco to participate in HCV vaccine efficacy trials and evaluate knowledge of vaccine trial concepts: placebo, randomization and blinding. During 2006 and 2007, a total of 67 participants completed the survey. A substantial proportion (88%) would definitely (44%) or probably (44%) be willing to participate in a randomized trial, but knowledge of vaccine trial concepts was low. Reported willingness to participate in an HCV vaccine trial decreased with increasing trial duration, with 67% of participants surveyed willing to participate in a trial of 1 year duration compared to 43% of participants willing to participate in a trial of 4 years duration. Willingness to enroll in HCV vaccine trials was higher in young IDU than reported by most at-risk populations in HIV vaccine trials. Educational strategies will be needed to ensure understanding of key concepts prior to implementing HCV vaccine trials.
Levy
Vivian
V
San Mateo County Health Systems, San Mateo, CA, USA.
Evans
Jennifer L
JL
Stein
Ellen S
ES
Davidson
Peter J
PJ
Lum
Paula J
PJ
Hahn
Judith A
JA
Page
Kimberly
K
D000328:Adult; D002986:Clinical Trials as Topic; D003430:Cross-Sectional Studies; D055030:Drug Users / Q000706:statistics & numerical data*; D005260:Female; D007722:Health Knowledge, Attitudes, Practice; D006526:Hepatitis C / Q000517:prevention & control*; D006801:Humans; D008297:Male; D010358:Patient Participation / Q000706:statistics & numerical data*; D014761:Viral Hepatitis Vaccines; D055815:Young Adult
D014761:Viral Hepatitis Vaccines